Eyelid melanoma

Summary

Eyelid melanoma (MONDO:0000928) is a cancer. A subtype of cutaneous melanoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	eyelid melanoma
Mondo ID	MONDO:0000928
DOID	DOID:10040
NCIT	C4358
SNOMED CT	231834005
UMLS	C0339116
MedGen	90937
GARD	0022848
Anatomy (UBERON)	UBERON:0001711
Is cancer (heuristic)	yes

Also known as: eyelid melanoma · eyelid melanoma (disease) · malignant eyelid melanoma · malignant melanoma of eyelid · malignant melanoma of the eyelid · melanoma (disease) of eyelid · melanoma of eyelid · melanoma of the eyelid

Disease family

This is a subtype of cutaneous melanoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › skin cancer › cutaneous melanoma › eyelid melanoma

Related subtypes (9): balloon cell malignant melanoma, nodular malignant melanoma, acral lentiginous melanoma, amelanotic skin melanoma, superficial spreading melanoma, lentigo maligna melanoma, desmoplastic melanoma, spitzoid melanoma, melanoma in congenital melanocytic nevus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.